Cargando…

Use of imaging modalities for decision-making in inflammatory bowel disease

Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nancey, Stéphane, Fumery, Mathurin, Faure, Mathias, Boschetti, Gilles, Gay, Claire, Milot, Laurent, Roblin, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912556/
https://www.ncbi.nlm.nih.gov/pubmed/36777362
http://dx.doi.org/10.1177/17562848231151293
_version_ 1784885230841102336
author Nancey, Stéphane
Fumery, Mathurin
Faure, Mathias
Boschetti, Gilles
Gay, Claire
Milot, Laurent
Roblin, Xavier
author_facet Nancey, Stéphane
Fumery, Mathurin
Faure, Mathias
Boschetti, Gilles
Gay, Claire
Milot, Laurent
Roblin, Xavier
author_sort Nancey, Stéphane
collection PubMed
description Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recurrence of Crohn’s disease and a negative disease course. Therefore, both imaging modalities are emerging as pivotal diagnostic tools to achieve the emerging therapeutic target of transmural healing associated with better disease outcomes. Despite its numerous potential advantages over endoscopy and even MRE and its good availability, IUS is still widely underused to monitor and manage inflammatory bowel disease (IBD) patients and help in making clinical decisions in routine practice. This situation is clearly due to the absence of validated, reliable, and responsive indices, as well as the lack of trained gastroenterologists and radiologists, as IUS is a component of radiologist expertise in several countries but not yet integrated into the training program of gastroenterologists. However, there is an increasing body of evidence in the literature that IUS and MRE are both becoming essential imaging resources to help clinicians in making reliable decisions. Here, we discuss the up-to-date evidence about the usefulness and performance of cross-sectional imaging, focusing on the ability of bowel US and MRE to aid clinical decision-making for the optimal management and monitoring of IBD.
format Online
Article
Text
id pubmed-9912556
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-99125562023-02-11 Use of imaging modalities for decision-making in inflammatory bowel disease Nancey, Stéphane Fumery, Mathurin Faure, Mathias Boschetti, Gilles Gay, Claire Milot, Laurent Roblin, Xavier Therap Adv Gastroenterol Review Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recurrence of Crohn’s disease and a negative disease course. Therefore, both imaging modalities are emerging as pivotal diagnostic tools to achieve the emerging therapeutic target of transmural healing associated with better disease outcomes. Despite its numerous potential advantages over endoscopy and even MRE and its good availability, IUS is still widely underused to monitor and manage inflammatory bowel disease (IBD) patients and help in making clinical decisions in routine practice. This situation is clearly due to the absence of validated, reliable, and responsive indices, as well as the lack of trained gastroenterologists and radiologists, as IUS is a component of radiologist expertise in several countries but not yet integrated into the training program of gastroenterologists. However, there is an increasing body of evidence in the literature that IUS and MRE are both becoming essential imaging resources to help clinicians in making reliable decisions. Here, we discuss the up-to-date evidence about the usefulness and performance of cross-sectional imaging, focusing on the ability of bowel US and MRE to aid clinical decision-making for the optimal management and monitoring of IBD. SAGE Publications 2023-02-09 /pmc/articles/PMC9912556/ /pubmed/36777362 http://dx.doi.org/10.1177/17562848231151293 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Nancey, Stéphane
Fumery, Mathurin
Faure, Mathias
Boschetti, Gilles
Gay, Claire
Milot, Laurent
Roblin, Xavier
Use of imaging modalities for decision-making in inflammatory bowel disease
title Use of imaging modalities for decision-making in inflammatory bowel disease
title_full Use of imaging modalities for decision-making in inflammatory bowel disease
title_fullStr Use of imaging modalities for decision-making in inflammatory bowel disease
title_full_unstemmed Use of imaging modalities for decision-making in inflammatory bowel disease
title_short Use of imaging modalities for decision-making in inflammatory bowel disease
title_sort use of imaging modalities for decision-making in inflammatory bowel disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912556/
https://www.ncbi.nlm.nih.gov/pubmed/36777362
http://dx.doi.org/10.1177/17562848231151293
work_keys_str_mv AT nanceystephane useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT fumerymathurin useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT fauremathias useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT boschettigilles useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT gayclaire useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT milotlaurent useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease
AT roblinxavier useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease